Canaccord Genuity Starts Halozyme Therapeutics (HALO) at Buy
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $113.90 -1.15%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $8.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Starts Jenoptik AG (JEN:GR) at Buy
- JPMorgan Starts Mobility Global (MBGL) at Neutral
- Freedom Broker Starts Autoliv, Inc. (ALV) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
